SCN2A Encephalopathy Clinical Trials and Treatments

Nerve cells talk to each other with electrical pulses, and those pulses depend on tiny doors in the cell membrane that let sodium in. SCN2A carries the instructions for one of those doors, a channel called Nav1.2. A change in the gene can jam the door open, so the cell fires too easily, or stick it shut, so the cell cannot fire well enough.

The most common symptoms of SCN2A Encephalopathy include Seizures beginning in the first days or months of life, often of several types and often hard to control, Developmental delay, or loss of skills a child had already gained, Autism or autism-like behavior, with or without seizures, Low muscle tone, feeding difficulty and trouble with balance or coordination, Abnormal movements such as stiffening, jerking or writhing, among others. No reliable population count exists; the FamilieSCN2A Foundation describes SCN2A as a leading single-gene cause of infantile seizures, autism and intellectual disability, and estimates that about 75% of cases are still undiagnosed. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for SCN2A Encephalopathy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. No drug has been approved specifically for SCN2A encephalopathy, and the first decision is close. Relutrigine (PRAX-562), from Praxis Precision Medicines, is a small-molecule drug that dampens the persistent sodium current that overactive channels leak.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to SCN2A Encephalopathy. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

SCN2A Encephalopathy is caused by variants in the SCN2A gene. The gene test finds the variant; a separate interpretation of whether it is gain or loss of function guides which seizure medicines are safe.

It follows Autosomal dominant, almost always a new (de novo) change; an affected parent has a 50% chance of passing it on inheritance. No reliable population count exists; the FamilieSCN2A Foundation describes SCN2A as a leading single-gene cause of infantile seizures, autism and intellectual disability, and estimates that about 75% of cases are still undiagnosed. Genetic testing confirms the diagnosis.

Yes. Genetic testing for SCN2A Encephalopathy looks at the SCN2A gene. The gene test finds the variant; a separate interpretation of whether it is gain or loss of function guides which seizure medicines are safe.

It follows Autosomal dominant, almost always a new (de novo) change; an affected parent has a 50% chance of passing it on inheritance.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for SCN2A Encephalopathy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a SCN2A Encephalopathy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.